A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 15, Issue 12, 2013, Pages 1120-1127

  Freemantle, N ^a   Balkau, B ^b,c   Home, P D ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

CREDIT study; HbA1c; Hypoglycaemia; Insulin regimens; Propensity score

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROPENSITY SCORE; RISK ASSESSMENT; WEIGHT GAIN;

CREDIT STUDY; HBA1C; HYPOGLYCAEMIA; INSULIN REGIMENS; PROPENSITY SCORE;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULINS; MALE; MIDDLE AGED; PROPENSITY SCORE; TREATMENT OUTCOME;

EID: 84887200674     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12147     Document Type: Article

References (13)

1. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006; 23: 579-593.
2. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
3. Rodbard HW, Blonde L, Braithwaite SS et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13(Suppl 1): 1-68.
4. Holman RR, Thorne KI, Farmer AJ et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730.
5. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
6. Freemantle N, Balkau B, Danchin N et al. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes Obes Metab 2012; 14: 901-909.
7. Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis. Cardiovasc Diabetol 2009; 8: 9.
8. Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study. Cardiovasc Diabetol 2009; 8: 3.
9. 1chieve study. Diabetes Res Clin Pract 2011; 94: 352-363.
10. Karter AJ, Subramanian U, Saha C et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care 2010; 33: 733-735.
11. Peyrot M, Rubin RR, Lauritzen T et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28: 2673-2679.
12. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
13. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442-451.